Thermo Fisher Scientific Inc. has completed its acquisition of PPD, Inc., a global provider of clinical research services to the biopharma and biotech industry, for $17.4 billion.
WILMINGTON, N.C.--(BUSINESS WIRE)--PPD, Inc. (Nasdaq: PPD) has been recognized as one of the best in the world for its successful employee learning and development programs by the Association for Talent Development (ATD), a global organization that empowers and supports professionals to develop talent in the workplace.
PPD, Inc. (Nasdaq:Â PPD), a leading global contract research organization, today reported its financial results for the second quarter ended June 30, 2021.
PPD Recognized as a Best Place to Work in Asia
WILMINGTON, N.C. & LOS ANGELES--(BUSINESS WIRE)--PPD, Inc. (Nasdaq: PPD), a leading global contract research organization (CRO), and Science 37, developer of the Decentralized Clinical Trial Operating System™ (DCT OS), today announced an innovative collaboration in which PPD will be fully enabled to design, build, test, implement and execute digital trials using Science 37's DCT SaaS-based technology platform.
As part of its ambition to become the world’s largest patient access and site conduct organization, CRO PPD has snapped Bioclinica’s research site biz.
Accelerated Enrollment Solutions (AES), a business unit of Pharmaceutical Product Development, LLC (PPD), has acquired the clinical research site business of Bioclinica, expanding AES’ global footprint and solidifying its leadership position in patient access and site conduct. AES services now extend across five continents, 20 countries, over 180 research sites and more than 100 million households.
Harbour BioMed and Pharmaceutical Product Development, LLC (PPD) entered a strategic collaboration to develop HBM’s therapeutics in the fields of oncology and immunology.
PPD is working with Cancer Treatment Centers of America to speed up enrollment into cancer studies.
WILMINGTON, N.C.--(BUSINESS WIRE)-- Evidera, a business unit of Pharmaceutical Product Development, LLC (PPD) and a leading provider of evidence-based solutions demonstrating the real-world effectiveness, safety and value of health care products, has entered into an agreement to acquire Medimix International, a global technology company providing real-world evidence (RWE) insights and information to the pharmaceutical, diagnostic and medical device industries. The acquisition will enable Evidera to offer its customers enhanced technology solutions, real-world data and access to health care providers